Abstract 1324
Background
Tumour markers are widely used for screening and monitoring cancers. CA 15-3 and CEA are FDA-approved tumour markers for monitoring breast cancer. However, the prognostic efficacy of preoperative elevation of CEA and CA15-3 levels in breast cancer remains controversial.
Methods
We retrospectively analyzed the clinicopathological parameters and preoperative serum CEA and CA 15-3 level of 149,238 patients of Korean Breast Cancer Society Registry (KBCSR) Database who underwent surgery between January 2000 and December 2015.
Results
The patients with elevated CA 15-3/CEA level had shown more advanced T stage and N stage, ER negativity, PR negativity and HER2 positivity compared the patients with normal CA15-3/CEA levels. The patients with elevated CA 15-3/CEA level had worse OS than the patients with normal CA 15-3/CEA level. In survival analysis, both elevated group had worst prognosis compared other groups. In subgroup analysis by subtypes, in luminal A, both elevated group had hazard ratio (HR) 2.14 (95% CI 1.01-4.55), only CA 15-3 elevated had HR 2.38 (95% CI 1.58-3.58) and only CEA elevated group had HR 1.79 (95% CI, 1.20-2.68), compared normal group. In luminal B, both elevated group had HR 3.99 (95% CI 2.23-7.16), only CA 15-3 elevated had HR 2.38 (95% CI 1.58-3.58) and only CEA elevated group had HR 1.79 (95% CI, 1.20-2.68), compared normal group. In HER2 subtype group, elevated CEA level was the only independent prognostic factor. However, in TNBC, elevated preoperative CEA and CA 15-3 level were not a significant prognostic factor for OS.
Conclusions
The elevation of preoperative tumor markers was associated with aggressive characteristic and worse overall survival. Preoperative tumor markers predicted the prognosis of the patients and showed differences according to subtypes. In luminal breast cancer, the CA 15-3 elevation has higher hazard ratio than the CEA elevation and the patients with both tumor markers showed the worst prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3879 - Efficacy of derazantinib (DZB) in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) expressing FGFR2-fusion or FGFR2 mutations/amplifications
Presenter: Michele Droz Dit Busset
Session: Poster Display session 2
Resources:
Abstract
4679 - It’s Not Only About Weight Loss: Tackling Pancreatic Cancer-Associated Cachexia
Presenter: Ana Leonor Matos
Session: Poster Display session 2
Resources:
Abstract
2276 - Frequency and clinicopathological characteristics of biliary tract carcinomas harboring the FGFR2-fusion gene: a prospective observational study (PRELUDE study)
Presenter: Masafumi Ikeda
Session: Poster Display session 2
Resources:
Abstract
2773 - Post-hoc analyses of a subgroup of patients with advanced biliary tract cancer (BTC) who crossed over to treatment with etoposide toniribate (EDO-S7.1) in a randomized Phase II study
Presenter: Ulrich-Frank Pape
Session: Poster Display session 2
Resources:
Abstract
4479 - Capecitabine +Best supportive care (BSC) or Erlotinib +BSC has Overall survival (OS) benefit over BSC alone in unresectable/metastatic Gall bladder cancer(GBC) patients with ECOG PS-III. Results from a phase II Randomised controlled trial (RCT)
Presenter: Babita Kataria
Session: Poster Display session 2
Resources:
Abstract
4843 - FGFR2 fusions and its effect of patient (pt) outcomes in intrahepatic cholangiocarcinoma (iCCA)
Presenter: Daniel Almquist
Session: Poster Display session 2
Resources:
Abstract
2324 - The Clinical Outcomes of Systemic Chemotherapy in Patients with Unresectable or Metastatic Combined Hepatocellular-cholangiocarcinoma (HCC-CCA): Retrospective Study of 120 Patients
Presenter: Eojin Kim
Session: Poster Display session 2
Resources:
Abstract
3678 - High PD-L1 expression is associated with treatment response to pembrolizumab in patients with advanced biliary tract cancer.
Presenter: Gilhyang Kim
Session: Poster Display session 2
Resources:
Abstract
3901 - Genomic profiling in Chinese biliary tract cancer patients with PI3K/AKT/mTOR pathway and RAS gene mutations
Presenter: Jingyu Cao
Session: Poster Display session 2
Resources:
Abstract
4390 - Phase II trial of trifluridine/tipiracil (TAS-102) in patients with advanced refractory biliary tract cancer (BTC)
Presenter: Sakti Chakrabarti
Session: Poster Display session 2
Resources:
Abstract